News

LGBTQ Nation7hOpinion
Trump’s abandonment of the fight against HIV comes as researchers say they’re on the cusp of victory
Tens of thousands of deaths and new HIV infections will be the direct result of Donald Trump’s abandonment of PEPFAR and ...
Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats
Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...
Gilead eyes Kymera’s ‘adhesive’ cancer drug in $750m deal
Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.
A University of Utah doctor’s research led to a major HIV drug. He worries federal cuts will stop people from getting it.
The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...
Durban's young health professionals lead the way in HIV prevention and clinical trials
Discover how young healthcare innovators from Durban are transforming clinical trials and community health, earning accolades ...
San Francisco Examiner16h
Coverage questions mute enthusiasm for HIV drug approval
Lenacapavir, created by Foster City-based Gilead Sciences, has been in use for several years as a treatment for HIV/AIDS ...
The Pharma Letter18h
Yeztugo holds potential to address key unmet needs for PrEP usage
Last week the US Food and Drug Administration approved Gilead Sciences Yeztugo (lenacapavir) for the prevention of HIV ...
Promise of Victory Over H.I.V. Fades as U.S. Withdraws Support
A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much ...
The Observer21h
Ugandan firm to manufacture $28,000 HIV drug for just $50
In a bold step toward global health justice, Ugandan biotech company DEI BioPharma has announced it will begin manufacturing ...